TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03057873

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein, high fiber dietary supplement
Description: Dry powder to be mixed with 10 ounces of cold water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powder to be mixed with 10 ounces of cold water
Study: NCT02355093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adductor canal block (ACB)
Description: We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block (FNB)
Description: the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Study: NCT04630015

Intervention type: OTHER
Intervention: Survey Administration
Description: Participants will complete study specific survey
Study: NCT02605694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
Study: NCT01333618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: curving introducer Günther Tulip Filter
Description: The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark) The amplitude of introducer curvature was 5°-15° less than the angle between the inferior vena cave axis and the approached iliac vein axis and the distance between the vertex of the curved angle and the hook of the filter was 2-4cm less than the distance between the level of the renal vein confluence and the furcation of inferior vena cave.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: straight introducer Günther Tulip Filter
Description: The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark)
Study: NCT02524080

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Triage to optimal healthcare level
Description: Triage to optimal healthcare level

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Triage to optimal healthcare level
Description: Triage to optimal healthcare level
Study: NCT01070355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid free fatty acid
Description: An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules taken twice daily for 2-6 weeks before liver resection.
Study: NCT04652024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anorectal manometry
Description: , patients are instructed to isolate the anal sphincter and puborectalis muscles and improve its strength by using modified Kegel exercises in lying position with a probe in situ. Visual and verbal feedback techniques are used to reinforce the maneuvers, as they are being performed. The anal and rectal pressure changes displayed on the monitor provides visual feedback to the patient.
Study: NCT02072096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: Administered orally
Study: NCT03098407

Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine
Description: This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
Study: NCT02072096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (QW)
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide twice daily (BID)
Description: Administered SC
Study: NCT01591564

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpersonal Psychotherapy for youth with SMD (IPT-SMD)
Description: Youth will receive weekly therapy sessions for 16 weeks and then bi-weekly session until week 20. Parent sessions will also be included.
Study: NCT03774537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplantation of hUC-MSCs
Description: Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs through intravenous infusion. Dose A - 1 million cells per kg; Dose B - 5 million cells per kg

Intervention type: DRUG
Group type: OTHER
Intervention: No transplantation of hUC-MSCs
Description: Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
Study: NCT02799992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 689 nm Laser Treatment of the Macula

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Half Dose Photodynamic Therapy
Study: NCT00841022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information with comics
Description: Information of children with comic leaflet
Study: NCT04220606

Intervention type: DRUG
Group type: OTHER
Intervention: Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)

Intervention type: DRUG
Group type: OTHER
Intervention: Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)
Study: NCT01177657

Intervention type: PROCEDURE
Intervention: Stool sampling
Description: Stool samples collected and checked for the presence of rotavirus
Study: NCT01325909

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise programme
Study: NCT03098407

Intervention type: DRUG
Group type: OTHER
Intervention: Methadone
Description: This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
Study: NCT03626974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Venipuncture
Description: Venipuncture for blood collection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Venipuncture
Description: Venipuncture for blood collection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffuser spreading odor
Description: Diffuser will place under a Hood with an air-flow

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Diffuser spreading odor
Description: Diffuser will place under a Hood with an air-flow
Study: NCT01556633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamiflu (oseltamivir)
Description: Single dose of Tamiflu in volunteers on dialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamiflu (oseltamivir)
Description: Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
Study: NCT02905773

Intervention type: OTHER
Group type: OTHER
Intervention: root canal therapy
Description: effect of devices ( ProTaper and Reciprocal Files)

Intervention type: OTHER
Group type: OTHER
Intervention: root canal retreatment
Description: effect of devices ( ProTaper and Reciprocal Files)
Study: NCT01171521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermaClose Group
Description: The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
Study: NCT03667131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Maleate
Description: Enalapril Maleate 5 mg tablet, every 12 hrs for 90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 5 mg tablet, every 12 hrs for 90 days.
Study: NCT04627350

Intervention type: OTHER
Intervention: Response to pulmonary finding (nodule, mass)
Description: Follow-up low-dose CT, PET-CT, tissue sampling (transparietal biopsy, bronchoscopy, resection), contrast-enhanced CT of the thorax
Study: NCT02097199

Intervention type: OTHER
Intervention: Increased sports workload
Description: At least 150 minutes of moderate or 75 minutes of vigorous exercise per week. The Recommendations for Adults From the American College of Sports Medicine and the American Heart Association clearly define physical exercise intensity levels. The present study follows these recommendations. Consequently, moderate physical activity can be reached by e.g. quick walking, slow bicycling, slow swimming...; it is also possible to reach the expected workload by engaging in vigorous exercise (e.g. jogging/running, quick swimming, playing soccer/tennis...). The gain in performance will objectified by performing a bicycle stress test at the beginning and the end of the study.
Study: NCT01729832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breast reconstruction
Description: Undergo DIEP flap breast reconstruction using the StealthStation navigation system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoperative imaging
Description: Undergo DIEP flap breast reconstruction using the StealthStation navigation system
Study: NCT00804440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Tablets, 800 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Tablets, 800 mg
Study: NCT00120250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eszopiclone
Description: The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
Study: NCT04443777

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: Both groups will perform the resistance training protocol that will consist of a warm-up on the bench press and leg press, both with workload at 50% of 1-RM. After a 2-minute rest, the resistance training session will be started. It will consist of 4 sets of bench press and leg press exercises at 65% of 1-RM with maximum repetitions until concentric failure, with the execution speed of 2x2. The bench press exercises will be followed by the leg press exercises with no interval between them. A 2-minute interval will allowed after each series of exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Both groups will perform the resistance training protocol that will consist of a warm-up on the bench press and leg press, both with workload at 50% of 1-RM. After a 2-minute rest, the resistance training session will be started. It will consist of 4 sets of bench press and leg press exercises at 65% of 1-RM with maximum repetitions until concentric failure, with the execution speed of 2x2. The bench press exercises will be followed by the leg press exercises with no interval between them. A 2-minute interval will allowed after each series of exercises.
Study: NCT04772924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fasting
Description: more than 12 hour of fasting as ceremony of Ramadan

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: not fasting
Description: preferred not to take long term fasting
Study: NCT01525511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B
Description: Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets
Study: NCT00177346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAS with cerebral protection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAS without cerebral protection
Study: NCT01850381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM608
Description: For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
Study: NCT02857465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
Study: NCT00585585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betahistine dihydrochloride
Description: oral, 50-300 mg, daily
Study: NCT02857465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
Study: NCT01415440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosing will parallel that of Lisdexamfetamine.
Study: NCT03453086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block(TPVB) group
Description: Thoracic paravertebral block group (TPVB) group: The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes.Tuohy needle will be introduced in a cephalad direction. The tip of the needle will be advanced under direct visualization until it pierces the superior costo-transverse ligament. When the needle tip is located immediately above the pleura, the needle is aspirated to confirm the absence of blood or air.~Serratus anterior plane block group (SAP) group: The US probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the 5th rib is identified in the midaxillary line. The latissimus dorsi, teres major and serratus muscles will be then easily identifiable by US overlying the fifth rib. The needle will be introduced in-plane with respect to the US probe from supero-anterior to postero-inferior

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block(TPVB) group
Description: Thoracic paravertebral block group (TPVB) group: The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes.Tuohy needle will be introduced in a cephalad direction. The tip of the needle will be advanced under direct visualization until it pierces the superior costo-transverse ligament. When the needle tip is located immediately above the pleura, the needle is aspirated to confirm the absence of blood or air.~Serratus anterior plane block group (SAP) group: The US probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the 5th rib is identified in the midaxillary line. The latissimus dorsi, teres major and serratus muscles will be then easily identifiable by US overlying the fifth rib. The needle will be introduced in-plane with respect to the US probe from supero-anterior to postero-inferior
Study: NCT01538173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250ml HES 6%
Description: Application twice a day 250ml HES 6% for three days postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 9% NaCl 500ml
Description: Application twice a day 500ml 9% NaCl for three days postoperatively.
Study: NCT03163030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Description: Electrical Stimulation of the Vagus Nerve
Study: NCT01948310

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
Study: NCT03067831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: Transplantation of purified autologous bone marrow-derived stem cells.
Study: NCT02128581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39
Description: use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39
Description: use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT03340805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride.
Study: NCT04541342

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: initial arthroscopy with medial opening-wedge high tibial osteotomy fixed by a plate system then second look arthroscopy with plate removal
Description: It is a joint preserving procedure especially preferred in young patients for whom arthroplasty is not desirable. The procedure promotes regeneration by causing lateral shift of the weight-bearing axis, thus decreasing load on the medial compartment and widening the medial joint space.Many of the patients complains of irritation through the plate and wish metal removal after healing of the osteotomy.All patients will undergo initial arthroscopy before high tibial osteotomy (HTO). During arthroscopy, debridement of the degenerate tissues and meniscal tears if present will be performed. Then opening-wedge high tibial osteotomy (OWHTO) will be performed and fixed by a plate system. Second-look arthroscopy will be conducted at the time of plate removal after healing of the osteotomy. This will be after about 6 months up to one year.